Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion
Gilead Sciences is nearing a deal to buy biotech Immunomedics and its prized breast-cancer drug for more than $20 billion, according to people familiar with the matter.
Dow Jones & Company, Inc. 4300 U.S. Route 1 North Monmouth Junction, NJ 08852 You are currently subscribed as newsletter@newslettercollector.com. For further assistance, please contact Customer Service at support@wsj.com or 1-800-JOURNAL.
Copyright 2020 Dow Jones & Company, Inc. | All Rights Reserved.